AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
VALION BIO INC
US
SIC 3845 · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
FIGI BBG00PT2YC13
0.91▲ 0.39 (75.36%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.52
Day's Range
0.52 – 0.57
52-Week Range
0.51 – 1.21
Volume
106.9K
Avg Volume
350.0K
Share Statistics
Shares Outstanding
Employees
—
Exchange
US
Listed
—
Share count as of August 14, 2026

VALION BIO INC (VBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about VALION BIO INC (VBIO)
What is VALION BIO INC's Market Cap?
VALION BIO INC's Market Cap is $20.2M, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's Enterprise Value?
VALION BIO INC's Enterprise Value is $18.1M, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's EV / EBITDA?
VALION BIO INC's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's Net Income (TTM)?
VALION BIO INC's Net Income (TTM) is -$18.8M, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's EBITDA?
VALION BIO INC's EBITDA is -$16.5M, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's Diluted EPS (TTM)?
VALION BIO INC's Diluted EPS (TTM) is -0.84, based on as-reported figures from SEC (XBRL) filings.
What is VALION BIO INC's Net Debt?
VALION BIO INC's Net Debt is -$2.1M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021
OPERATING EXPENSES
Research and development—
Selling, general and administrative—
Total operating expenses—
Loss from operations—
OTHER (EXPENSE) INCOME
Change in fair value of derivative liability—
Interest income—
Interest expense—
Net other (expense) income—
Net loss from operations before discontinued operations—
Net loss
Net loss per share attributed to common stockholders - basic and diluted (in dollars per share)—